Improved sensitization effect of sunitinib in cancer cells of the esophagus under hypoxic microenviroment

Yuqiong Ding, Qin Qin, Yan Yang, Xinchen Sun, Xi Yang, Hongcheng Zhu, Xiaochen Chen, Hao Zhang, Yuehua Yang, Lei Gao, Judong Luo, Xifa ZhouOncology 2016 · DOI

Abstract

Radiotherapy is widely used in esophageal squamous cell carcinoma (ESCC) treatment. Promoting the radiation sensitivity of cancer cells is required. Recent studies have shown that sunitinib can inhibit the growth of several cancer lines. However, few studies on the radiosensitive effect of sunitinib on ESCC cells under hypoxic conditions have been conducted. In the present study, the radiosensitive effects of sunitinib on human ESCC cells were assessed, and the underlying mechanisms were explored. ESCC cells were exposed to hypoxia and treated with sunitinib at different concentrations prior to irradiation. Sunitinib potently inhibited ESCC cell proliferation in an MTT assay. In a clonogenic survival assay, sunitinib sensitized hypoxic ESCC cells to radiation, with sensitizing enhancement ratios of 1.31-1.59. In addition, sunitinib promoted the apoptosis of ESCC cells, but did not alter their cell cycle distribution. Radiosensitization was accompanied by inhibition of the radiation-induced upregulation of hypoxia-inducible factor (HIF)-1α and vascular endothelial growth factor (VEGF) expression. Thus, sunitinib confers radiosensitivity to esophageal cancer cells, which is associated with the downregulation of HIF-1α and VEGF expression. Sunitinib can be a promising radiosensitizer for esophageal cancer radiotherapy.

Introduction

Esophageal squamous cell carcinoma (ESCC) remains a major global health challenge with high mortality rates. While radiotherapy is a cornerstone of treatment, its effectiveness is often limited by the tumor's own microenvironment. Solid tumors often contain "hypoxic" zones—areas with very low oxygen levels. This is problematic because radiation therapy relies on oxygen to create free radicals that damage cancer DNA. Furthermore, hypoxia triggers a survival response in cancer cells, led by Hypoxia-Inducible Factor 1-alpha (HIF-1α), which acts as a master switch to turn on genes like VEGF for angiogenesis and stress endurance. This study investigates whether sunitinib, a multi-targeted tyrosine kinase inhibitor, can act as a radiosensitizer to break this resistance in ESCC cells.

Methods

The researchers used the ECA109 human ESCC cell line to test their hypothesis through several standard assays. Cells were placed in a specialized chamber maintaining 0.5–1.0% oxygen to mimic the interior of a solid tumor. Cell viability and long-term survival were measured using MTT and clonogenic survival assays, respectively. Flow cytometry was employed to analyze apoptosis (Annexin V/PI staining) and cell cycle distribution. Finally, Western blotting was used to quantify the protein levels of HIF-1α and VEGF to confirm the underlying biochemical mechanism. The study compared normoxic cells against hypoxic cells treated with varying doses of sunitinib (1 or 2.5 µM) and X-ray radiation.

Results

Proliferation and Radiosensitivity

Sunitinib inhibited ESCC cell growth in a dose-dependent manner, with an IC50 of 7.07 µM at 24 hours. In hypoxic cells, treatment with 2.5 µM of sunitinib reduced the surviving fraction at 2 Gy (SF2) from 0.67 down to 0.58. The study achieved a Sensitizing Enhancement Ratio (SER) of 1.31 to 1.59, indicating that radiation was roughly 30-60% more effective when sunitinib was present.

Figure 1: Sunitinib inhibits ECA-109 cell proliferation under hypoxic conditions and enhances the effect of ionizing radiation (IR).

Apoptosis and Cell Cycle Distribution

Flow cytometric analysis showed that the combination of sunitinib and radiation triggered significantly higher rates of apoptosis than either treatment alone. Interestingly, sunitinib did not significantly change the cell cycle distribution. While many radiosensitizers work by trapping cells in the radiation-sensitive G2/M phase, sunitinib's effect appears to be independent of cell cycle redistribution.

Figure 2: Sunitinib promotes apoptosis (A, C) but does not significantly alter cell cycle distribution (B, D) in ECA-109 cells.

Molecular Mechanism

Western blots revealed that while hypoxia causes a massive spike in HIF-1α and VEGF proteins, the addition of sunitinib effectively blunted this response, particularly at the 2.5 µM dose. This suggests that sunitinib works by directly suppressing the molecular survival signals induced by hypoxia.

Discussion and Conclusion

This study provides a strong biochemical rationale for using sunitinib as a radiosensitizer for difficult-to-treat, oxygen-starved esophageal tumors. By downregulating HIF-1α and VEGF, sunitinib removes the molecular "shield" that cancer cells use to survive radiation under hypoxia.

However, there are limitations to consider. This research was conducted entirely in vitro; the complex environment of a living organism could alter these effects. Future work is needed to determine the optimal clinical timing and dosage for combining sunitinib with radiotherapy in human patients to maximize tumor killing while minimizing side effects. In summary, sunitinib represents a promising adjunct therapy to improve the outcomes of radiotherapy in esophageal cancer.

Summary updated

Abstract

Radiotherapy is widely used in esophageal squamous cell carcinoma (ESCC) treatment. Promoting the radiation sensitivity of cancer cells is required. Recent studies have shown that sunitinib can inhibit the growth of several cancer lines. However, few studies on the radiosensitive effect of sunitinib on ESCC cells under hypoxic conditions have been conducted. In the present study, the radiosensitive effects of sunitinib on human ESCC cells were assessed, and the underlying mechanisms were explored. ESCC cells were exposed to hypoxia and treated with sunitinib at different concentrations prior to irradiation. Sunitinib potently inhibited ESCC cell proliferation in an MTT assay. In a clonogenic survival assay, sunitinib sensitized hypoxic ESCC cells to radiation, with sensitizing enhancement ratios of 1.31-1.59. In addition, sunitinib promoted the apoptosis of ESCC cells, but did not alter their cell cycle distribution. Radiosensitization was accompanied by inhibition of the radiation-induced upregulation of hypoxia-inducible factor (HIF)-1α and vascular endothelial growth factor (VEGF) expression. Thus, sunitinib confers radiosensitivity to esophageal cancer cells, which is associated with the downregulation of HIF-1α and VEGF expression. Sunitinib can be a promising radiosensitizer for esophageal cancer radiotherapy.
BibTeX
@inproceedings{ding2016improved,
  author = {Yuqiong Ding and Qin Qin and Yan Yang and Xinchen Sun and Xi Yang and Hongcheng Zhu and Xiaochen Chen and Hao Zhang and Yuehua Yang and Lei Gao and Judong Luo and Xifa Zhou},
  title = {{Improved sensitization effect of sunitinib in cancer cells of the esophagus under hypoxic microenviroment}},
  booktitle = {Oncology},
  year = {2016},
  doi = {10.3892/ol.2016.5247},
}
Figure